This ppt gives an overview of the Indian Pharmaceutical sector. We have concentrated on 5 aspects of the sector and analysed it. The covered heads are history, business model, Marketing, Competitor analysis, Financials and Trends.
Indian pharmaceutical industry: Policies, achievements and challengesRajesh Kochhar
Indian pharmaceutical industry is a success story from a national as well as third-world perspective. India accounts for 10% of world production and ranks third in the world in terms of volume. In value terms the share is only 1.4% and the rank 14th.
his statistic underlines the important fact that India produces world-class generic drugs at a very low cost. Indian domestic pharma market, currently evaluated at $12 bn, is largely self-sufficient with patented drugs playing a minimal role.
Pharmaceutical market india a comprehensive industry analysis - Reports CornerReports Corner
"1.0 Summary
“Pharmaceutical Market: India, A Competitive Industry Analysis” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.
The Indian pharmaceutical market is set to become the eight largest pharma market globally by 2015. In 2012 it was worth $13 billion. It is forecast to reach $50 billion by 2015 and increase its dominance as a leading player in Asia. It is predicted that the Indian pharma market will be a significant global competitor by 2020 with an expected worth of up to $74 billion.
This report describes the current therapeutics that are propelling the biopharmaceutical market in India. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.
This study reveals market figures of the overall Indian pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.
https://www.reportscorner.com/reports/15826/Pharmaceutical-Market:-India-A-Comprehensive-Industry-Analysis/
The Indian markets and financial institutions stand out as sound, stable and better
regulated in contrast to developed economies. As a result, India can continue to be an
attractive market in view of its strong and stable fundamentals and the resilience which
Indian economy has displayed so far
Indian pharmaceutical industry: Policies, achievements and challengesRajesh Kochhar
Indian pharmaceutical industry is a success story from a national as well as third-world perspective. India accounts for 10% of world production and ranks third in the world in terms of volume. In value terms the share is only 1.4% and the rank 14th.
his statistic underlines the important fact that India produces world-class generic drugs at a very low cost. Indian domestic pharma market, currently evaluated at $12 bn, is largely self-sufficient with patented drugs playing a minimal role.
Pharmaceutical market india a comprehensive industry analysis - Reports CornerReports Corner
"1.0 Summary
“Pharmaceutical Market: India, A Competitive Industry Analysis” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.
The Indian pharmaceutical market is set to become the eight largest pharma market globally by 2015. In 2012 it was worth $13 billion. It is forecast to reach $50 billion by 2015 and increase its dominance as a leading player in Asia. It is predicted that the Indian pharma market will be a significant global competitor by 2020 with an expected worth of up to $74 billion.
This report describes the current therapeutics that are propelling the biopharmaceutical market in India. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.
This study reveals market figures of the overall Indian pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.
https://www.reportscorner.com/reports/15826/Pharmaceutical-Market:-India-A-Comprehensive-Industry-Analysis/
The Indian markets and financial institutions stand out as sound, stable and better
regulated in contrast to developed economies. As a result, India can continue to be an
attractive market in view of its strong and stable fundamentals and the resilience which
Indian economy has displayed so far
Introduction Indian Pharmaceutical market, SWOT analysis, PEST Analysis, Timeline analysis of Sun Pharma, Glaxo Smith Kline, Mankind, CIPLA and Zydus Cadila.
indian Pharmaceutical industry export import overviewbipindapin
Pharmaceutical Industry-EXPORT IMPORT INDIA
The pharmaceutical industry develops, produces, and markets drugs or pharmaceuticals licensed for use as medications. Pharmaceutical companies are allowed to deal in generic and/or brand medications and medical devices
Trends & Opportunities for Indian Pharma is a knowledge paper highlighting the upcoming trends and related opportunities in Indian pharmaceuticals industry
India is among the top six global pharmaceutical producers in the world. Indian vaccines are exported to 150 countries. India produces 40-70 per cent of the WHO demand for DPT & BCG and 90 per cent of measles vaccine. Approximately 70 per cent of the patients in developing countries receive Indian medicines through NGOs like The Clinton Foundation, Bill & Melinda Gates Foundation, Doctors without Borders, the UNCTAD etc.
Advantages of Pharma in India, Market Share and Economic Drivers, Structure of Pharma Sector, Evolution of Pharma, Revenue %, Market Share, Porter 5 Force Model, BCG Matrix, Government Policies, Opportunities.
Each year, the U.S. biopharmaceutical industry spends billions of dollars on intensive research to discover new medicines for patients. Though the research process is long, uncertain, and expensive, the treatments that eventually result save lives and improve the health of people all around the world. Recent decades have seen enormous progress in the fight against major causes of death and disability, including cancer, HIV/AIDS, mental illness, and diabetes, as well as against numerous rare diseases. In addition, advances by companies in the biopharmaceutical sector play an important role in controlling costs of health care by reducing hospitalizations, surgeries, and other costly care.
Biopharmaceutical research and development is an investment in people, services, ideas and products.
This dynamic and innovative industry directly supports hundreds of thousands of jobs and indirectly supports millions more across the United States. The sector contributes significantly to the economy on the national, state, and local levels.
The 2012 Pharmaceutical Industry Profile explores the critical role that biopharmaceutical companies play in the lives of patients and in the U.S. economy. Chapter 1 describes recent advances in medicines and the value medicines bring to patients and the health care system. Chapter 2 discusses the positive economic impact of the industry and describes several key challenges facing the industry today. Chapter 3 describes major programs that ensure that people have access to the medicines they need.Chapter 4 explains the research and development (R&D) process and how the biopharmaceutical industry fits into the vibrant life sciences ecosystem. Through ongoing efforts to advance science and translate research findings into new medicines, biopharmaceutical companies bring value every day to patients, their families, and the entire economy.
Introduction Indian Pharmaceutical market, SWOT analysis, PEST Analysis, Timeline analysis of Sun Pharma, Glaxo Smith Kline, Mankind, CIPLA and Zydus Cadila.
indian Pharmaceutical industry export import overviewbipindapin
Pharmaceutical Industry-EXPORT IMPORT INDIA
The pharmaceutical industry develops, produces, and markets drugs or pharmaceuticals licensed for use as medications. Pharmaceutical companies are allowed to deal in generic and/or brand medications and medical devices
Trends & Opportunities for Indian Pharma is a knowledge paper highlighting the upcoming trends and related opportunities in Indian pharmaceuticals industry
India is among the top six global pharmaceutical producers in the world. Indian vaccines are exported to 150 countries. India produces 40-70 per cent of the WHO demand for DPT & BCG and 90 per cent of measles vaccine. Approximately 70 per cent of the patients in developing countries receive Indian medicines through NGOs like The Clinton Foundation, Bill & Melinda Gates Foundation, Doctors without Borders, the UNCTAD etc.
Advantages of Pharma in India, Market Share and Economic Drivers, Structure of Pharma Sector, Evolution of Pharma, Revenue %, Market Share, Porter 5 Force Model, BCG Matrix, Government Policies, Opportunities.
Each year, the U.S. biopharmaceutical industry spends billions of dollars on intensive research to discover new medicines for patients. Though the research process is long, uncertain, and expensive, the treatments that eventually result save lives and improve the health of people all around the world. Recent decades have seen enormous progress in the fight against major causes of death and disability, including cancer, HIV/AIDS, mental illness, and diabetes, as well as against numerous rare diseases. In addition, advances by companies in the biopharmaceutical sector play an important role in controlling costs of health care by reducing hospitalizations, surgeries, and other costly care.
Biopharmaceutical research and development is an investment in people, services, ideas and products.
This dynamic and innovative industry directly supports hundreds of thousands of jobs and indirectly supports millions more across the United States. The sector contributes significantly to the economy on the national, state, and local levels.
The 2012 Pharmaceutical Industry Profile explores the critical role that biopharmaceutical companies play in the lives of patients and in the U.S. economy. Chapter 1 describes recent advances in medicines and the value medicines bring to patients and the health care system. Chapter 2 discusses the positive economic impact of the industry and describes several key challenges facing the industry today. Chapter 3 describes major programs that ensure that people have access to the medicines they need.Chapter 4 explains the research and development (R&D) process and how the biopharmaceutical industry fits into the vibrant life sciences ecosystem. Through ongoing efforts to advance science and translate research findings into new medicines, biopharmaceutical companies bring value every day to patients, their families, and the entire economy.
India pharmacy retail market report -2020 |India Pharmacy Retail MarketKen Research Pvt ltd.
India Pharmacy Retail Market Outlook to 2020 – Growth Driven by Surge in OTC Drugs Sales and Expansion of Online Pharmacies” provides a comprehensive analysis of the various aspects such as market size of the India Pharmacy Retail and Online Pharmacy Retail Market. The report also covers the market segmentation on the basis of organized & unorganized pharmacies, prescribed drugs, OTC drugs & private label products, category of drugs and generic & patented drugs. The report shares the company profile and competitive landscape for major players in the organized pharmacy sector and online pharmacy market.
Pharmacy retail market in India is driven by growth in the pharmaceutical sector, registered revenues of INR ~ billion in FY’2015. With the advent of online pharmacy retailers in the market, the industry is likely to witness a surge in the coming future. The retail pharmacy in the India has escalated at a CAGR of 19.4% from INR ~ billion in FY’2010 to INR ~ billion in FY’2015. The surge in growth is chiefly guided by the escalation in urbanization, increase in household expenditures, increasing smartphone users, need for convenience and rising literacy rate in the country coupled with growing medical awareness.
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...Irish Pereira
By Mr. Irish Pereira. The report present snapshot of Indian Pharmaceutical industry in both domestic as well as export market. It is collation of facts pertaining to Indian pharma exports and explore key emerging trends pertaining to pharma export market. It describes key players of Indian pharma market and their export orientation as in their target export destinations, their focus therapies etc.
Fact sheet:
1) Indian Pharma Market size 2015
2) Indian pharmaceutical market segments by value
3)Patented (Innovator) Vs Generics Scenario
4)Growth drivers of Indian pharmaceutical industry
5) Indian Pharmaceutical sector – SWOT Analysis
6)PHARMEXCIL – Facilitating agency for Indian Pharma Exports
7) Indian Pharmaceutical Exports (USD bn)
8)Formulations share in Total Pharma Exports (2014-15)
9) Top 25 destination countries of India’s pharmaceutical exports during 2013-14 (INR mn)
10) Major Indian Pharma Companies (By Revenue-USD mn)
11) Pharma players and their export destinations
Sun Pharma,Dr. Reddy’s Lab,
CIPLA, Lupin, Aurobindo, Cadila Healthcare, Torrent Pharma, Wockhardt,
12) Emerging trends in Indian Pharma Market
Indian Pharma Market - IPM Overview June 2015Anup Soans
Major Highlights for Month of June 2015:
...................................................................
Indian Pharma Market (IPM) clocked 7928 Crs in June 2015
........................................................................
IPM grew at 14.8% for the month of June 2015
...................................................................................
Companies:
For the month of June 2015, among the top 10, Sun* grew by 27.9% followed by Pfizer at 20.2% & Abbott* at 19.0%
.........................................................................................................
23 companies crossed the growth of IPM for the month of June 2015 among top 50
...............................................................................................
Among the top 50, Wockhardt has the highest growth of 36.2% followed by AstraZeneca at 35.4% & Glenmark at 34.5 %
..................................................................................................
27 Co's showed growths more than 10% among the top 50
............................................................................................
Among the 11-20 ranked, Glenmark has the highest growth of 34.5% followed by Torrent at 28.3% & USV at 27.1%
..................................................................................................
Among the 21-30 ranked, Wockhardt has the highest growth at 36.2% followed by MSD* 31.6% & Unichem at 20.5% & Novo Nordisk at 18.9%
......................................................................................................
Among the 31-40 ranked, AstraZeneca has the highest growth at 35.4% followed by Akumentis at 33.4% & JBCPL at 27.0%
....................................................................................................
Among the 41-50 ranked, Hetero has the highest growth at 21.0% followed by Fourrts at 17.9% & Allergan at 17.8%
..............................................................................................
Among the 51-60 ranked, Boehringer grew at 79.1% followed by Eli Lilly at 39.9% & Troikaa at 38.4%
..............................................................................................
Among the 61-70 ranked, Fresenius Kabi grew at 38.8% followed by RPG at by 36.1% followed by TTK at 26.3%
..............................................
AstraZeneca enters the 500 Cr Club, Hetero 400 Crs, Troikaa 300 Crs, Tablets India 200 Crs on MAT Basis
Our presentation for Pharma Sector.
Problem statement: You are Pfizer and your major blockbuster drug, Lipitor ($12 bn in sales in 2008, ~20% of your total revenue), is going off-patent in 2011. A decline in the sales of Lipitor is inevitable and you are looking to make a major move into emerging economies where growth in pharma sales is the highest. How would you go about doing this?
Research Project on Factors affecting Employees Satisfaction
Phamaceutical sector in india
1. Indian Pharmaceutical Sector
A presentation by
Deepak Kumar
Dipankar Biswas
Kasif Iqbal
Partho Sarathi Roy
Shireen Khan
2. Inception & Snapshot
Bengal $21.73
Chemicals and 1.4 million
Pharmaceuticals
billion employment
(1892) industry per year
Alembic
Chemical works
(1907)
Bengal Immunity
(1919) Ranks
10 % of among top
Calcutta Chemicals,
Standard global five
Pharmaceuticals, production countries
Indian
Cipla etc. by volume
Pharmac
GSK, Parke Davis, eutical
Wyeth, Ciba etc. Sector
3. Time for Big Boys
1 2 3
Hindustan
Antibiotics IDPL (1961) Ranbaxy
(1954) (1961)
Evolution of Major Drugs
1920 1930 1940 1948
4. Game Changing Move
Landmark
IDMA was formed Patent act was
in 1961 passed in 1970
India could
Aim was to oppose manufacture any
monopoly international drug
5. Division of Drugs
Chronic Therapy Acute Therapy
Segment Segment
Indian
Pharmaceutical
Industry
Bulk drugs or
Formulations
API Cardiovascular Anti infective
Neurological Gastro intestinal
Anti-diabetes Respiratory
Oncology Pain management
6. Location of major pharmaceutical
companies in India
4000
3500
3000
No. of Companies
2500
2000
1500
1000
500
0
Others
Tamil Nadu
Maharashtra
Gujrat
West Bengal
Andhra Pradesh
Formulations
Bulk Drugs
7. Top Players
Ranbaxy
Sun Pharmaceuticals
Dr. Reddy’s Labortories Ltd.
Cipla
Lupin
8. Strength
Vast market growth potential
Low cost production
Low R&D costs
Innovative manpower
Cheap/skilled English-speaking labor force
Increasing western work methods and mindset
Long-established trade patterns with Western Europe and
the US
Strong local manufacturing sector
Governmental focus and investment in the R&D area
Increasing FDI in the industry
9. Weakness
Low pharma consumption levels per capita
Biased drug pricing and bad compensation policy
Underdeveloped healthcare infrastructure
Vast regional disparities in healthcare coverage
Many pharma MNCs already supplying the market at
lower prices
10. Opportunities
Large and growing population
Rising demand for generic drugs globally
Increased demand for APIs – active pharmaceutical
ingredients
Increasing R&D activity by domestic firms
11. Threats
Failure to properly enforce WTO compliant patent
legislation for drugs.
Government imposing further price controls on
essential medicine
India’s patent laws threatened by litigation
Weak copy right policies threatening the legal entities
in the industry
12. Porter’s Five Force Model
Power of supplier
Very low bargaining power
Threat of Substitutes
Barriers to Entry
Industry Competition No substitute for the
Very low barrier to medicine
entry
Highly competitive Biotechnology is a
threat to synthetic
pharma product
Power of Buyers
Consumer has no
choice but to buy what
doctor says
13. Industry Competition
Most competitive industries in the country with as
many as 10,000 different players.
Top player in the country has only 6% market share
and top five have 18%.
High growth prospects.
Very low entry barriers.
Fixed cost requirement is low and need for working
capital is high.
14. Bargaining Power of Buyers
End user of the product is different from the
influencer (read Doctor).
Consumer has no choice but to buy what doctor says.
Buyers are scattered and they as such does not wield
much power in the pricing of the products.
15. Bargaining Power of Suppliers
Pharma industry depends upon several organic
chemicals.
Very competitive and fragmented industry.
Chemicals are largely a commodity.
Suppliers have very low bargaining power.
Pharma industry can switch from their suppliers
without incurring a very high cost.
16. Barriers to Entry
Most easily accessible industries for an entrepreneur in
India.
Capital requirement for the industry is very
low, creating a regional distribution network is easy.
Point of sales is restricted in this industry in India.
Creating brand awareness and franchisee amongst
doctors is the key for long-term survival.
Quality regulations by the government may put some
hindrance for establishing new manufacturing
operations.
Impending new patent regime will raise the barriers to
entry.
17. Threat of Substitutes
One of the great advantages of the pharma industry.
Demand for pharma products continues and the
industry thrives.
Key reasons for high competitiveness in the industry
is that as an on going concern.
Key reasons for high competitiveness in the industry
is that as an on going concern.
18. Revolution in Marketing
International Trade Barriers have disappeared
Indian Industry is competing globally
Evolution of Internet, giving access to whole lot of
information, 137 million internet connection in india
Evolution of smart phones (sales growth by 87%)
Recognition of India’s intellectual capabilities
Report by: IAMAI, IMRB & Cyber Media Research
19. Global Pharma Market
Market Growth
Market size Market Growth Forecast
Region
Yr 2008 ( USD CAGR (2003 -
Billion) 2008) CAGR (2011 - 2015)
North
America 311.8 5.70% -1% to 2%
Europe 247.5 6.40% 3% to 6%
Japan 76.6 2.70% 1% to 4%
China 21 20% 23%
India 7.7 14.60% 12.20%
Global Sales 773.2 6.60% 3% to 6%
23. Supply Chain Model
Manufacturer Repackager
Retailer
Wholesaler
Manufacturer
Retailer
Repackager
Wholesaler
Wholesaler
Manufacturer Retailer
Other Sources of Drugs
(foreign, private mfrs)
24. Challenges in Pharma Supply Chain
Supply Inventory
chain cost effectiveness
Logistic
Planning
effectiveness
Supply
Time to
chain Responsiveness
market
challenges
25. Margins at Different Level
Levels Margins
Clearing and forwarding agents 1–10% on the total turnover + other expenses
Stockist or distributors 8% on scheduled drugs
10% on nonscheduled drugs
Retailers 16% on scheduled drugs
20% on nonscheduled drugs
26. Balance Sheet Overview
Companies
Market Cap Sales Turnover Net Profit Assets
Name
Rs. in Crores
Ranbaxy Labs 21,551.69 7,690.12 -3,052.05 6,258.36
Sun Pharma 78,776.72 4,015.56 1,927.98 8,148.91
Cipla 34,758.47 6,977.50 1,123.96 7,562.48
Dr Reddys
32,607.28 6,739.70 912.36 8,251.20
Labs
Lupin 26,750.90 5,384.83 804.37 4,727.06
27. DuPont Analysis
Cipla pharmaceutical ROE and ROI has highest
returns on equity and Investment by 23.10 and 0.21
followed by Dr. Reddy’s Laboratories ROE is 17.00
and ROI is 0.18. The third position secured by
Ranbaxy Laboratories ROE is 16.16 and ROI by
0.13. This shows Cipla is concentrating on its
financial performance by reducing its expenses and
cost.
Company Logo
33. Acquisitions by MNCs
No Year Acquirer Target Company
Company Country
1 Jun’08 Daiichi Sankyo Co Ltd Japan Ranbaxy Laboratories
2 Aug’08 Fresenius Kabi AG Germany Dabur Pharma
3 Jun’09 Pfizer (Animal Health U.S. Vetnex Animal Health Ltd
Business) (earlier ICICI Venture
acquired from Ranbaxy)
4 Jun’09 Vetoquinol SA France Wockhardt (Animal Care
Subsidiary)
5 Jul’09 Abbott Laboratories U.S. Wockhardt (Nutrition
Business)
6 Jul’09 Sanofi Aventis France through Shantha Biotech (Hiked stake
Merieux Alliance from 60% to 80%)
7 May’10 Abbott Laboratories USA Piramal Healthcare(Sale of
Business)
34. Trends in Diseases
Tuberculosis
Especially in urban centres like Mumbai, Delhi,
Hyderabad, Kolkata etc.
Dengue Fever- 97 % increase in number of cases and
34 % increase in number of deaths
Swine flu- Worst affected areas are MP, UP,
Rajasthan
Encephalitis- 50% decrease in the last 2 years, lack of
funds could play spoilsports
Lifestyle diseases- Heart diseases, Cancer, Obesity,
Diabetes etc. is set to rise
35. Clinical Trial Boom
Huge amount of outsourcing from Europe and USA
Highly trained man power
Advanced IT infrastructure
Large amount of patients to experiment
Expected to employ 50,000 medical professionals by
2017
WHO report, 2011
36. Recommendations
Stringent patent laws must be imposed. Many patents are
rejected by USPTO and EPO.
Pharmaceuticals mergers and acquisition should be
scanned closely by the Competition commission of India
Price regulation should be balanced in such a way that it
does not affect the Pharmaceutical business
Assisting SME’s in overcoming entry barriers posed by
GMP compliance requirement
Absence of provision on regulation of biosimilars
Transparency and accountability in the drug regulatory
regime
Editor's Notes
Report by IAMAI(internet and mobile association of india & IMRB, growth of 16% compared to last year. MOBILE – 6 million -11.2 million